Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J. Motzer, Theodore Stewart Gourdin, Camillo Porta et al.|Journal of Clinical Oncology|2024Cited by 170
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih‐Hsin Yang, Tibor Csőszi, Baohui Han et al.|Journal of Thoracic Oncology|2023Cited by 55
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind studyJames Chih‐Hsin Yang, Tibor Csőszi, Alexander Luft et al.|Annals of Oncology|2021Cited by 20
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Song Qu, Mikhail Klochikhin et al.|Journal of Clinical Oncology|2026Cited by 0